A Toll-like receptor 7 single nucleotide polymorphism protects from advanced inflammation and fibrosis in male patients with chronic HCV-infection

Journal of Hepatology

Volumn 47, Issue 2, 2007, Pages 203-211

  Schott, Eckart ^a   Witt, Heiko ^a   Neumann, Konrad ^a   Taube, Stefan ^b   Oh, Djin Ye ^a   Schreier, Eckart ^b   Vierich, Sandra ^a   Puhl, Gero ^a   Bergk, Alexandra ^a   Halangk, Juliane ^a   Weich, Viola ^a   Wiedenmann, Bertram ^a   Berg, Thomas ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b ROBERT KOCH INSTITUTE   (Germany)

Author keywords

Fibrosis; Genetic polymorphism; HCV; Innate immunity; Toll like receptor

Indexed keywords

INTERLEUKIN 6; TOLL LIKE RECEPTOR 7;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENE SEQUENCE; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HEPATITIS C; HUMAN; HUMAN TISSUE; INFLAMMATION; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; FEMALE; GENE FREQUENCY; GENOTYPE; GUANINE; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; SEVERITY OF ILLNESS INDEX; SEX FACTORS; THYMINE; TOLL-LIKE RECEPTOR 7;

EID: 34347381278     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2007.03.021     Document Type: Article

References (51)

1. Cholet F., Nousbaum J.B., Richecoeur M., Oger E., Cauvin J.M., Lagarde N., et al. Factors associated with liver steatosis and fibrosis in chronic hepatitis C patients. Gastroenterol Clin Biol 28 (2004) 272-278
2. Poynard T., Ratziu V., Charlotte F., Goodman Z., McHutchison J., and Albrecht J. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis c. J Hepatol 34 (2001) 730-739
3. Bonkovsky H.L., Troy N., McNeal K., Banner B.F., Sharma A., Obando J., et al. Iron and HFE or TfR1 mutations as comorbid factors for development and progression of chronic hepatitis C. J Hepatol 37 (2002) 848-854
4. Wang H., Mengsteab S., Tag C.G., Gao C.F., Hellerbrand C., Lammert F., et al. Transforming growth factor-beta1 gene polymorphisms are associated with progression of liver fibrosis in Caucasians with chronic hepatitis C infection. World J Gastroenterol 11 (2005) 1929-1936
5. Hillebrandt S., Wasmuth H.E., Weiskirchen R., Hellerbrand C., Keppeler H., Werth A., et al. Complement factor 5 is a quantitative trait gene that modifies liver fibrogenesis in mice and humans. Nat Genet 37 (2005) 835-843
6. Powell E.E., Edwards-Smith C.J., Hay J.L., Clouston A.D., Crawford D.H., Shorthouse C., et al. Host genetic factors influence disease progression in chronic hepatitis C. Hepatology 31 (2000) 828-833
7. Muhlbauer M., Bosserhoff A.K., Hartmann A., Thasler W.E., Weiss T.S., Herfarth H., et al. A novel MCP-1 gene polymorphism is associated with hepatic MCP-1 expression and severity of HCV-related liver disease. Gastroenterology 125 (2003) 1085-1093
8. Sonzogni L., Silvestri L., De Silvestri A., Gritti C., Foti L., Zavaglia C., et al. Polymorphisms of microsomal epoxide hydrolase gene and severity of HCV-related liver disease. Hepatology 36 (2002) 195-201
9. Cella M., Jarrossay D., Facchetti F., Alebardi O., Nakajima H., Lanzavecchia A., et al. Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon. Nat Med 5 (1999) 919-923
10. Diebold S.S., Kaisho T., Hemmi H., Akira S., and Reis e Sousa C. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 303 (2004) 1529-1531
11. Heil F., Hemmi H., Hochrein H., Ampenberger F., Kirschning C., Akira S., et al. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 303 (2004) 1526-1529
12. Krug A., Towarowski A., Britsch S., Rothenfusser S., Hornung V., Bals R., et al. Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12. Eur J Immunol 31 (2001) 3026-3037
13. Lee J., Chuang T.H., Redecke V., She L., Pitha P.M., Carson D.A., et al. Molecular basis for the immunostimulatory activity of guanine nucleoside analogs: activation of Toll-like receptor 7. Proc Natl Acad Sci USA 100 (2003) 6646-6651
14. Horsmans Y., Berg T., Desager J.P., Mueller T., Schott E., Fletcher S.P., et al. Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection. Hepatology 42 (2005) 724-731
15. Lee J., Wu C.C., Lee K.J., Chuang T.H., Katakura K., Liu Y.T., et al. Activation of anti-hepatitis C virus responses via Toll-like receptor 7. Proc Natl Acad Sci USA 103 (2006) 1828-1833
16. Chaperot L., Blum A., Manches O., Lui G., Angel J., Molens J.P., et al. Virus or TLR agonists induce TRAIL-mediated cytotoxic activity of plasmacytoid dendritic cells. J Immunol 176 (2006) 248-255
17. Gibson S.J., Lindh J.M., Riter T.R., Gleason R.M., Rogers L.M., Fuller A.E., et al. Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod. Cell Immunol 218 (2002) 74-86
18. Du X., Poltorak A., Wei Y., and Beutler B. Three novel mammalian toll-like receptors: gene structure, expression, and evolution. Eur Cytokine Netw 11 (2000) 362-371
19. Scheuer P.J. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 13 (1991) 372-374
20. Stephens M., and Donnelly P. A comparison of bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet 73 (2003) 1162-1169
21. Schroder N.W., Diterich I., Zinke A., Eckert J., Draing C., von Baehr V., et al. Heterozygous Arg753Gln polymorphism of human TLR-2 impairs immune activation by Borrelia burgdorferi and protects from late stage Lyme disease. J Immunol 175 (2005) 2534-2540
22. Texereau J., Chiche J.D., Taylor W., Choukroun G., Comba B., and Mira J.P. The importance of Toll-like receptor 2 polymorphisms in severe infections. Clin Infect Dis 41 (2005) S408-S415
23. Smirnova I., Mann N., Dols A., Derkx H.H., Hibberd M.L., Levin M., et al. Assay of locus-specific genetic load implicates rare Toll-like receptor 4 mutations in meningococcal susceptibility. Proc Natl Acad Sci USA 100 (2003) 6075-6080
24. Van der Graaf C.A., Netea M.G., Morre S.A., Den Heijer M., Verweij P.E., Van der Meer J.W., et al. Toll-like receptor 4 Asp299Gly/Thr399Ile polymorphisms are a risk factor for Candida bloodstream infection. Eur Cytokine Netw 17 (2006) 29-34
25. Agnese D.M., Calvano J.E., Hahm S.J., Coyle S.M., Corbett S.A., Calvano S.E., et al. Human toll-like receptor 4 mutations but not CD14 polymorphisms are associated with an increased risk of gram-negative infections. J Infect Dis 186 (2002) 1522-1525
26. Barber R.C., Aragaki C.C., Rivera-Chavez F.A., Purdue G.F., Hunt J.L., and Horton J.W. TLR4 and TNF-alpha polymorphisms are associated with an increased risk for severe sepsis following burn injury. J Med Genet 41 (2004) 808-813
27. Montes A.H., Asensi V., Alvarez V., Valle E., Ocana M.G., Meana A., et al. The Toll-like receptor 4 (Asp299Gly) polymorphism is a risk factor for Gram-negative and haematogenous osteomyelitis. Clin Exp Immunol 143 (2006) 404-413
28. Tal G., Mandelberg A., Dalal I., Cesar K., Somekh E., Tal A., et al. Association between common Toll-like receptor 4 mutations and severe respiratory syncytial virus disease. J Infect Dis 189 (2004) 2057-2063
29. Hawn T.R., Verbon A., Lettinga K.D., Zhao L.P., Li S.S., Laws R.J., et al. A common dominant TLR5 stop codon polymorphism abolishes flagellin signaling and is associated with susceptibility to Legionnaires' disease. J Exp Med 198 (2003) 1563-1572
30. Lammers K.M., Ouburg S., Morre S.A., Crusius J.B., Gionchett P., Rizzello F., et al. Combined carriership of TLR9-1237C and CD14-260T alleles enhances the risk of developing chronic relapsing pouchitis. World J Gastroenterol 11 (2005) 7323-7329
31. Lazarus R., Klimecki W.T., Raby B.A., Vercelli D., Palmer L.J., Kwiatkowski D.J., et al. Single-nucleotide polymorphisms in the Toll-like receptor 9 gene (TLR9): frequencies, pairwise linkage disequilibrium, and haplotypes in three U.S. ethnic groups and exploratory case-control disease association studies. Genomics 81 (2003) 85-91
32. Kikuchi K., Lian Z.X., Kimura Y., Selmi C., Yang G.X., Gordon S.C., et al. Genetic polymorphisms of toll-like receptor 9 influence the immune response to CpG and contribute to hyper-IgM in primary biliary cirrhosis. J Autoimmun 24 (2005) 347-352
33. Torok H.P., Glas J., Tonenchi L., Bruennler G., Folwaczny M., and Folwaczny C. Crohn's disease is associated with a toll-like receptor-9 polymorphism. Gastroenterology 127 (2004) 365-366
34. Berghofer B., Frommer T., Konig I.R., Ziegler A., Chakraborty T., Bein G., et al. Common human Toll-like receptor 9 polymorphisms and haplotypes: association with atopy and functional relevance. Clin Exp Allergy 35 (2005) 1147-1154
35. Jacobson I.M., Ghalib R., Lawitz E., Freilich B., Gordon S.C., Kwo P., et al. Early viral response and on treatment response to CPG 10101 (Actilon TM), in combination with pegylated interferon and/or ribavirin, in chronic HCV genotype 1 infected patients with prior relapse response (abstract). Hepatology 44 (2006) 224A
36. Akira S., Uematsu S., and Takeuchi O. Pathogen recognition and innate immunity. Cell 124 (2006) 783-801
37. Harris N.L., and Senapathy P. Distribution and consensus of branch point signals in eukaryotic genes: a computerized statistical analysis. Nucleic Acids Res 18 (1990) 3015-3019
38. Galun E., Zeira E., Pappo O., Peters M., and Rose-John S. Liver regeneration induced by a designer human IL-6/sIL-6R fusion protein reverses severe hepatocellular injury. FASEB J 14 (2000) 1979-1987
39. Zimmers T.A., Pierce R.H., McKillop I.H., and Koniaris L.G. Resolving the role of IL-6 in liver regeneration. Hepatology 38 (2003) 1590-1591 author reply 1591
40. Bansal M.B., Kovalovich K., Gupta R., Li W., Agarwal A., Radbill B., et al. Interleukin-6 protects hepatocytes from CCl4-mediated necrosis and apoptosis in mice by reducing MMP-2 expression. J Hepatol 42 (2005) 548-556
41. Cooper S., Erickson A.L., Adams E.J., Kansopon J., Weiner A.J., Chien D.Y., et al. Analysis of a successful immune response against hepatitis C virus. Immunity 10 (1999) 439-449
42. Day C.L., Lauer G.M., Robbins G.K., McGovern B., Wurcel A.G., Gandhi R.T., et al. Broad specificity of virus-specific CD4+ T-helper-cell responses in resolved hepatitis C virus infection. J Virol 76 (2002) 12584-12595
43. Lauer G.M., Ouchi K., Chung R.T., Nguyen T.N., Day C.L., Purkis D.R., et al. Comprehensive analysis of CD8(+)-T-cell responses against hepatitis C virus reveals multiple unpredicted specificities. J Virol 76 (2002) 6104-6113
44. Sharp A., Robinson D., and Jacobs P. Age- and tissue-specific variation of X chromosome inactivation ratios in normal women. Hum Genet 107 (2000) 343-349
45. Offner P.J., Moore E.E., and Biffl W.L. Male gender is a risk factor for major infections after surgery. Arch Surg 134 (1999) 935-938 discussion 938-940
46. Kast R.E. Predominance of autoimmune and rheumatic diseases in females. J Rheumatol 4 (1977) 288-292
47. Molloy E.J., O'Neill A.J., Grantham J.J., Sheridan-Pereira M., Fitzpatrick J.M., Webb D.W., et al. Sex-specific alterations in neutrophil apoptosis: the role of estradiol and progesterone. Blood 102 (2003) 2653-2659
48. Posma E., Moes H., Heineman M.J., and Faas M.M. The effect of testosterone on cytokine production in the specific and non-specific immune response. Am J Reprod Immunol 52 (2004) 237-243
49. Marriott I., Bost K.L., and Huet-Hudson Y.M. Sexual dimorphism in expression of receptors for bacterial lipopolysaccharides in murine macrophages: a possible mechanism for gender-based differences in endotoxic shock susceptibility. J Reprod Immunol 71 (2006) 12-27
50. Imahara S.D., Jelacic S., Junker C.E., and O'Keefe G.E. The influence of gender on human innate immunity. Surgery 138 (2005) 275-282
51. Berghofer B., Frommer T., Haley G., Fink L., Bein G., and Hackstein H. TLR7 ligands induce higher IFN-alpha production in females. J Immunol 177 (2006) 2088-2096